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ABSTRACT 
  
The purpose of this IQP was to discuss the topic of transgenic animals, explore 
the reason for creating them, and assess their impact on society.  This paper examines 
how transgenic animals are made and the main types that have been created.  It also looks 
at their ethical and legal issues, and the impact of this new technology on society.  This 
paper concludes that, with oversight caution, transgenic technology should continue.  
Transgenic animals can have enormous medical benefits and could help curing disease. 
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                                                  EXECUTIVE SUMMARY 
 
 
 A transgenic animal is an animal that has been genetically altered so that it will 
produce a specific protein.  Foreign DNA has been inserted into the animal’s DNA so it 
will produce a protein it does not normally have.  They can be used for studying human 
diseases that the animals are not normally susceptible to, and can have strong medical 
benefits.  The foreign DNA can be inserted in a number of different ways.  It can be 
inserted by microinjection into a fertilized egg, where the DNA sequence is injected 
directly into the male pronucleus, or it can be created by delivering DNA in vitro to ES 
cells, then the ES cells are grown to the blastocyst stage and inserted in the uterus of a 
surrogate mother.  Adding and deleting genes in these animals provides them with new 
properties that make them useful for better understanding disease or manufacturing a cure. 
 Different types of transgenic animals have been invented to cater to specific 
societal needs.  Transgenic disease models are animals genetically altered to exhibit 
human pathologies that they do not normally have.  This can be helpful in studying a 
disease so that we may understand them and develop treatments.  Some human disease 
models that have been created so far in mice include HIV, Alzheimer’s, and Oncogenes.  
These models help us gain insight to what causes the disease and its progression.  
Transpharmers, Xenotransplanters, and transgenic food sources are other types of  
transgenic animals that have also been created.  Transpharmers are used for medicinal 
purpose by producing specific pharmaceutical proteins in their mammary gland to be 
consumed in the milk by people.  Xenotransplanters are animals, usually pigs because of 
their similar blood physiology to humans, which have been genetically altered to better 
prepare their organs for transplantation.  These are helpful because normally animal’s 
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organs are quickly rejected by the human body, so this could be a way to prevent that 
from happening.  The nearly limitless possibilities of the different transgenic animals that 
can be made will help serve society in the future when combating illness. 
 But should we make such animals?   Since it is unethical and immoral to use 
humans for testing new therapeutic drugs, disease model animals serve a strong benefit to 
society.  Models like Alzheimer’s mouse do not suffer noticeably, so with strong medical 
benefit and little animal suffering, such experiments should be allowed to proceed.  For 
models like oncomouse that involve tumor formation, the potential for suffering is much 
greater, so we are in favor of legislation mandating a minimization of animal suffering 
using pain killers and early sacrifice when possible. Since transpharmer animals likely 
don’t even realize they are manufacturing the drug in their milk, and since such drugs can 
save thousands of lives, we are also strongly in favor of transpharming.   Transgenic 
animals are a very controversial topic which requires close watch so that the animal has 
very minimal or if possible no suffering while maximizing the medical benefit.  
Superpigs are an example of animals that were given human growth hormone and they 
had to be put to sleep because they were immobile and their organs failed.  Thus we agree 
with the current moratorium on creating any new transgenic animals for food sources, 
other than fish with seem to tolerate growth hormone with few bad effects. 
 The legislation behind transgenic animals helps to keep this new technology from 
becoming an unethical source of scientific study, and we support of strong legislative 
oversight of transgenic experiments.  Patents on transgenic animals are a controversial 
topic.  Patents are a way to increase incentive for creating them, but some animal rights 
activists think that it is unethical to patent animal life.  There is no law that says living 
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things can’t be patented however.  Genetically altered bacteria, created for breaking down 
crude oil, have been patented for over 20 years now.  Initially turned down because they 
were thought to be a creation of nature, they were eventually allowed to be patented 
because it was recognized that they met all requirements under section 101 under Title 35 
of the United States code.  The oncomouse was also eventually patented in the US and 
Europe by Harvard.  It was controversial because it gave ownership of a mammalian 
species to a corporation for the first time.  This landmark case lead the way for allowing 
transgenic animals to be patented. 
 Transgenic animals have had enormous benefits to our society.  The methods used 
in creating them have opened up new possibilities in genetic research.  This new 
technology has opened up new doors in the study of human disease and treatment.  In our 
opinions, the benefits of transgenic animals out weigh the negatives so long as strong 
oversight is mandated minimizing potential animal suffering, and the impact that they 
have in helping treat disease is makes it almost unwise not to allow their use.  This new 
technology will become more defined as time progresses.  They will not only help save 
lives but they will improve upon the quality of life. 
 7 
PROJECT OBJECTIVE 
 
  
The objective of this IQP was to investigate various topics dealing with transgenic 
animal research providing a paper that should educate the reader about the kinds of 
transgenic animals that have been invented, familiarize the reader with the laws 
governing transgenic animals, and their moral and ethical issues.  Transgenic technology 
has been shown to have both positive and negative implications on society, making this 
new technology very controversial.  The research of this paper also helped the authors 
come to their own conclusion on whether to support transgenic technology.   
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CHAPTER 1:  INTRODUCTION TO TRANSGENIC ANIMALS 
 
 A transgenic animal is an animal where foreign DNA has been inserted into the 
animal’s DNA.  Transgenic animals are created so that the DNA in the animal expresses 
a specific protein that is not normally produced in that animal.  The uses of this 
technology are numerous.  The purpose of this chapter is to briefly introduce the topic of 
transgenesis, and to describe and contrast the main ways transgenic animals are created.   
 One of the most common uses of transgenic animals is to model human disease.  
Because the testing of new vaccines and drugs must first be performed on animals, 
animal disease models are required.  Yet many human diseases do not occur in animals, 
especially those animals convenient to work with like mice, so transgenic animals are 
created to mimic some aspect of human disease.  A gene deficiency is created so that the 
animal is more susceptible to a disease, or genes can be added to get the same result.   
 
Methods for Making Transgenic Animals 
Transgenic animals are usually made by cloning the transgene of interest (for 
example human insulin) then inserting that gene into the genome of a newly fertilized 
egg.  The egg is then cultured to the blastocyst stage and implanted into to uterus of a 
surrogate mother.   
One method of inserting foreign DNA into an egg is microinjecting it into the 
male pronucleus.  The male pronucleus is used because it is larger than the female 
pronucleus.  Eggs are matured using hormones to increase ovulation in a group of 
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animals.  Then the eggs are harvested and injected with hundreds of copies of the desired 
DNA using a micropipette (Transgenic Animals 2003) (Figure-1). 
 
 
Figure-1: Microinjection of DNA into a Pronucleus. 
http://www.medecine.unige.ch/transgenese/microinj.jpg 
If the procedure is a success, the animal produced will have altered DNA throughout 
every cell in its body.  But because of the randomness of this procedure, in some cases 
the DNA doesn’t integrate or only some of the cells have the new DNA sequence.  When 
this occurs the resulting animal is a “mosaic animal”, not all the cells contain the 
transgene DNA sequence.  The offspring of these particular animals will sometimes carry 
the gene and sometimes not.  A major benefit of making transgenic animals using 
microinjection is that it can be used on a wide variety of animals. 
Animal species Number of ova 
injected 
Number of offspring Number of 
transgenic 
offspring 
rabbit 1907 218 (11.4%) 28 (1.5%) 
sheep 1032 73 (7.1%) 1 (0.1%) 
pig 2035 192 (9.4%) 20 (1.0%) 
Table 1: The Efficiency of Microinjection period Figures in parentheses 
denote percent efficiency compared to original number of ova injected.  
(Transgenic Animals and Plants, 2005) 
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 A second technique for making a transgenic animal uses embryonic stem cells or 
ES cells to introduce the new DNA sequence. ES cells are cells that regenerate and 
differentiate into other cells.  They are undifferentiated cells that have the potential to 
differentiate into any type of cell, somatic cells or germ line cells, so if the transgene can 
be inserted into an ES cell, the cell can then be used to create the transgenic animal.  
These cells become very useful when it is important to target gene sequences to specific 
sites in the genome because ES cells can be incorporated into a blastocyst and 
differentiate normally or be grown in vitro (Figure-2, left side). 
 
 
Figure-2:  The Two main Ways to Create a Transtgenic Animal.  The left side 
depicts the injection of ES cells into a blastocyst.  The right side depicts the natural 
maturation of a fertilized egg into a blastocyst.    (http://www.agresearch.co.nz/ 
scied/ search/biotech/gene_gmomaking_animal.htm#stem) 
 
The process of making a transgenic animal using ES cells starts by obtaining ES 
cells from the blastocyst of donor mice. The cells are taken from an embryo that has not 
yet been implanted in the uterine wall.  The fertilized embryos are collected from female 
mice a few days after fertilization or the mice are given steroids that prevent implantation 
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while embryonic cell division occurs.  The embryos are harvested and cultured using an 
embryonic fibroblast feeder layer that produces leukemia inhibitory factor.  This factor 
will help reduce the differentiation of the cells.  The inner cell mass of the harvested 
embryos dissociates from Trophoblast cells.  This allow the ES cells from the inner cell 
mass to be selected individually for undifferentiated morphology, indicating their likely 
pluripotency, then they are allowed to grow and multiply.  The DNA is introduced into 
the ES cells by microinjection, viruses, chemicals, or electroporation.  Electroporation is 
a process that uses a pulse of high voltage to make cell membranes permeable and allow 
the introduction of new DNA.  The electric charge is passed through a plate with DNA 
layered on top of cells.  The negative charge of DNA caused by its phosphate residues is 
attracted to positive electrodes.  Once the DNA is absorbed in the cell, the DNA moves 
into the cytoplasm and integrates into the cellular DNA (Taconic, 2003). 
The cells become ES cell lines that can be evaluated for their potential as gene 
targeting tools or used in studies of cellular differentiation.  If the transgene successfully 
incorporated, the ES cells can be injected into a blastocyst, and the embryo implanted as 
before to make the transgenic animal. 
 
Microinjection of Eggs vs. ES Cells for Creating Transgenic Animals 
Microinjection of Eggs ES Cell-Mediated Gene Transfer 
Pros Cons Pros Cons 
One of the first 
technique to prove 
successful in 
mammals. 
 
Sometimes genes 
are over or under 
expressed resulting 
in a mosaic animal. 
 
Works well in mice, 
which are often 
used. 
Doesn't work well in 
all mammals. 
Works in a wide 
variety of mammals. 
DNA integration is 
a random process 
and DNA 
Helps in studying 
genetic control of 
developmental 
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sometimes inserts in 
a place where it's 
not expressed. 
processes. 
 
  Allows for precise 
targeting of defined 
mutations in the 
gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Comparison of Genetically Engineered Mice Created by Pronuclear Injection Vs 
ES Cells (Camper, 2005) period  
 
 A gene targeting process is used to introduce the desired DNA sequence into ES 
cells.  In gene targeting, a piece of DNA that carries the transgene or DNA sequence of 
interest is introduced into the ES cells of a mouse by electroporation.  Inside the ES cell 
the DNA sequence can insert directly in the intact genome at a specific region.  ES cells 
that successfully incorporate the sequence are added to an embryo in its early stages.  
This is done by either injecting the ES cells in an embryo or culturing them with it.  The 
ES cells and embryo cell develop together into a chimeric embryo.  The chimeric embryo 
Effects on neighboring genes Insertional mutation Other 
>$12,000 >$3000 Cost 
1.5 -2 years 6-9 months Time 
Usually same as endogenous Usually integration site 
dependent 
Expression 
Heterozygotes 1, homozygotes 2 Vari dominant able,  
1 to >100 
Copy number 
Targeted to endogenous Random Insertion site 
Recessive or dominant Dominant Genetic action 
ES DERIVED TRANSGENIC  
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is implanted in a surrogate mother.  When the chimeric mouse is born the color is usually 
different from that of the host because the gene for the coat color is often chosen to be 
from the ES cells genetic makeup and not the host.  This is an easy way to confirm the 
success of the procedure.  The chimera then carries the new gene in its germ line and can 
be selectively bred to establish the gene permanently in a new mouse (Taconic, 2003). 
 Another method for inserting the foreign DNA into the ES cells is to use viruses.  
A retroviruse can be modified so that it carries a desired DNA sequence in its DNA.  The 
disease causing genes are removed from the virus so disease is not introduced to the 
transgenic animal.  The virus can infect the ES cells with a specific gene but does not 
infect all of the ES cells with the retroviral DNA.  Germ line cells need to be infected for 
the procedure to be successful. 
 A third method used to deliver the new DNA into the ES cells is DNA 
microinjection.  This is done by microinjection of the DNA sequence into the ES cells in 
the blatocyst of the host animal.  This process produces a mosaic animal that does not 
always carry the transgene in its germ line. The process is often repeated to gain more 
transgenic animals. 
 A versatile approach to enhance the delivery of nonviral DNA involves 
complexation with cationic polymers, which can be designed to overcome the barriers to 
effective gene transfer.  DNA is packaged into a polymetric or scaffolding.  Liposomes 
are usually used to fuse to the ES cell membrane and insert the DNA.  Polylysine and 
plasmid DNA can also be used to make an attraction between biotin and avidin. A 
mixture of the biotin-modified and unmodified cationic polymers are electrostatically 
complexed with non-viral DNA and tethered to a substrate containing nonglycosylated 
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avidin.  The cells that were used, HEK293T and NIH/3T3, grew along the surface, then 
were directly exposed to the tethered complexes and are easily transformed. Transfection 
is a function of the surface DNA quantities and the number of tethers in the complex. 
This process has shown to be much more efficient than traditional bulk delivery (Segura 
and Shea, 2002). 
 The success rate for these methods of creating transgenic animals that can birth 
animals containing the transgene is very low.  If the genetic manipulation does not cause 
an abortion, the result is a first generation of animals that need to be tested for the 
expression of the transgene. Depending on the technique used, the first generation may 
result in chimeras, and various tissues need to be tested for transgene insertion. When the 
transgene has integrated into the germ cells, the so-called germ line chimeras are then 
inbred for 10 to 20 generations until homozygous transgenic animals are obtained and the 
transgene is present in every cell. At this stage, embryos carrying the transgene can be 
frozen and stored for subsequent implantation (Buy, 1997). 
 
Assays Used for Screening Transgenic Animals 
 There are several ways of testing the effectiveness of the transgenic method used 
to determine whether the transgene incorporated into the various tissues of the animal.  
Foreign DNA can be detected in the genome of a transgenic animal using either a 
Southern assay, or PCR.  One of the more reliable tests is the "Southern Blot" test.  A 
Southern blot is a method of identifying a specific DNA band on an agarose gel 
electrophoresis by marking specific DNA sequences (Answers.com).  This technique uses 
a restriction enzyme to split DNA at specific locations, and then the fragmented DNA is 
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put through an agarose gel (Figure 3).  An electric current is run through the agarose gel.  
DNA moves towards the positive electrodes because it is negatively charged.  The size of 
the DNA affects how far it migrates through the gel, the smaller DNA fragments have an 
easier time migrating through the gel, so those fragments move the farthest on the gel.  
The pattern of DNA in the gel is then blotted to a membrane that retains the pattern, but 
allows hybridization to a probe to illuminate a specific gene (like the transgene).  The 
DNA from the animal is compared with the position of the DNA of the transgenic DNA.  
If the sample contains the transgene, the transgenic DNA was successfully integrated into 
the animal’s cell. 
 
Figure-3:  Digital Printout of an Agarose Gel Electrophoresis  
Performed on Plasmid DNA (Answers.com). 
 
 A Western Blot is another way to determine if an animal's tissue is expressing the 
transgene, i.e. is making the transgenic protein.  This method takes into account that 
transgenic animals are engineered to produce specific protein.  These proteins can be 
detected in a similar way as the DNA in the southern blot.  In the western blot, whole cell 
 16 
extracts containing protein are electrophoresed to separate the proteins by size, and then 
blotted.  Lighter proteins will travel further.  The protein is then blotted to membrane 
made of nitrocellulose and a specific protein is visualized among the bands present using 
an antibody solution.  The antibody recognizes and attaches to the transgenic protein, 
allowing its detection.  If the protein that the antibody binds to is present in the sample 
the antibody will bind to it and it will create a dark spot in the gel (Figure-4) 
(Answers.com). 
Figure-4:  Picture of a Western Blot With 5 Vertical Lanes (Answers.com). 
 
An Enzyme Linked Immunosorbent Assay or ELISA is another technique used 
for screening transgenic animals.  It is used to measure the levels of antibodies found in 
the transgenic animal's serums, blood and urine. Animals produce antibodies when 
substances are introduced which are foreign to the body (Agresearch, 2001).  An antigen 
or protein is added to a plastic well to which it attaches.  The serum of the animal is then 
added and if the animal is positive for the antibodies to the protein, they will bind to the 
proteins.  Antigens attached to an enzyme are then added to the mixture and they will 
bind the antibodies.  The enzymes react with a chromogen substrate to produce a color 
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(Figure-5).  If the color changes then the animal is positive for the antibodies against the 
transgenic protein. 
 
Figure-5:  Diagram of an ELISA Test.  An antigen (usually the 
transgenic protein) (blue sphere) is used to coat the well of a 
microtiter dish.  Blood or urine from the test animal is added to the 
well.  If it contains antibodies against the transgenic protein they bind 
the walls of the dish (green). Antibodies containing enzymes are then 
used to bind the former antibodies (pink).  Substrate is added. This 
part is a chemical reaction. The substrate reacts with the conjugate 
and forms a colour that you can see. By using a colourimeter and 
measuring the optical density of the solution, the technician is able to 
determine the number of antibody sites available (Agresearch, 2001). 
 
 The type of transgenic animal to be made is a very important question.  There are 
several factors that need to be taken into account when deciding what animals need to be 
used.  Disease models are usually mice since they have a short gestation time which 
allows more data to be obtained.  Transpharmers are usually cows, sheep, or goats since 
they produce large quantities of milk containing the product.  It is important to look at the 
gestation time, number of progeny, and amount of milk per year of the animal depending 
on what it is to be used for.  Transgenic animals are very useful and help scientists gain a 
better understanding of animal and human biological function. 
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CHAPTER 2:  TRANSGENIC ANIMAL EXAMPLES 
 
 
 This chapter will describe some of the categories of transgenic animals, and 
which transgenic animals have been made so far.  Some of the uses include disease 
models, food sources, and bioreactors for producing medication for humans.  Transgenic 
animals help us to better understand human disease and improve health care. 
 
Transgenic Disease Models 
 Transgenic animal disease models are animals that have been genetically altered 
to have traits that mimic the symptoms of specific human pathologies.  The disease 
models are needed so that we can better understand the disease for treatment.  Many 
animals do not normally exhibit the equivalent of certain human diseases.  So a human 
transgene specific to the disease needs to be expressed in the animal.  This allows for 
pathological characteristics in the animal so that it can be studied.  Animal disease 
models are very useful in that they allow us to screen drugs that may be harmful or have 
bad side affects.  Once the therapeutic agents have been discovered and tested, human 
cells may then be tested, followed by human test subjects in clinical trials.  But because it 
is not ethical or safe to perform the initial tests in humans, we use transgenic animals. 
 
AIDS MOUSE 
 This animal is a mouse that was used for studying human immunodeficiency virus 
or HIV.  The mouse has a transgene that encodes for the genome of type 1 HIV.  Mice 
normally lack the receptor and co receptor that allows them to be infected with HIV.  The 
mice were genetically altered to contain the gene for human CD4 promoter upstream of 
the human CD4 gene and human CKR-5 co-receptor gene.  These genes were inserted 
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into a newly fertilized mouse zygote and then transferred into the uterus of a female 
mouse.  Pups from the mouse litter were selected for their phenotypic correlation with 
human HIV (see below).  The production of the co-receptors in the mice allows for the 
HIV virus to attach to the T cells.  The mouse will then have the ability to synthesize all 
the viral proteins that aid the HIV in successfully infecting it (Hanna, 1998). 
 The AIDS mouse was designed to exhibit symptoms similar to human AIDS such 
as wasting, atrophic lymphoid organs, atrophic kidneys, and early death.  Studying these 
mice has led to the identification of human host factors that play critical roles in the type 
1 HIV replication cycle.  Thus, these studies have not only contributed towards our basic 
understanding of type 1 HIV life-cycle, they have also provided us with novel targets for 
future therapeutic intervention.  Table 1 below shows various types of HIV animal 
models. 
 
Animal 
Model 
Virus 
Challenge 
Model Characteristics Comments 
Mouse 
 Transgenic 
 HIV-1  
transgenic 
 Xenograft 
HIV-1 
None 
HIV-1 
Expression of human CD4, human co-
receptor 
Expression of HIV-1 gene products 
Varies, dependent on tissue type 
engrafted 
No spreading infection 
Developed AIDS-like 
pathologies 
T cell depletion 
Rat 
 Transgenic 
 HIV-1 
Transgenic 
HIV-1 
None 
Expression huCD4 and huCCR5 
LTR-driven expressions of HIV-1 gene 
product 
Poor virus spread, no 
replication of T 
lymphocytes 
Developed AIDS-like 
pathologies 
Rabbit 
 Transgenic 
HIV-1 Expression of huCD4 and T 
lymphocytes 
Inefficient virus spread 
Drosophila None Inducible, ubiquitous expressions of 
HIV-1 Tat 
Similarities to AIDS-like 
neuropathologies 
Cat FIV Replication of FIV, a related lentivirus Development of 
immunodeficiency, 
somewhat similar to AIDS 
Table 1: Small animal models for lentiviral disease have been developed that permit a certain level of in 
vivo analysis.  They all suffer from one major limitation: it is unclear how relevant they are in terms of 
HIV-1 infection in man (Van Maanen, 2005). 
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ALZHEIMER'S MOUSE 
 Alzheimer's is a disease marked by the loss of cognitive ability, and associated 
with the development of abnormal tissues and protein deposits in the cerebral cortex.  It is 
a neurological disease that affects the memory.  The impairment to the brain is due to the 
accumulation of neurotoxic precursors to and build up of amyloid proteins, which form a 
plaque in the brain (Figure-1). 
 
 
Figure-1:  A large human amyloid deposit (lighter color) in the frontal cortex of the 
novel Alzheimer's mouse (Photo courtesy of Bruce T. Lamb, Ph.D.) (Bowers, 1999). 
 
The amyloid-beta protein is initially soluble (and highly toxic to neuronal cells), and its 
buildup eventually causes the degeneration of neurons and their neurotransmitters in the 
brain (Games et al, 1995). 
 Expression of a mutant version of human amyloid precursor protein (APP) 
mRNA, holo-APP, and A-beta in the brains of the mice (which are associated with an 
aggressive early onset type of Alzheimer’s disease) causes them to exhibit human-like 
Alzheimer's disease symptoms (Games et al, 1995).  The mice also develop 
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neurofibrillary tangles.  The mouse model develops many of the neuropathological 
symptoms of AD in a temporal and regional dependent manner. 
 This model has been very useful for AD research. The Alzheimer's mouse in one 
experiment developed most of the pathologic changes seen in human brains with the 
exception of neurofibrillary tangles. This observation may cause a reconsideration of the 
pathogenesis of the disease, suggesting that these tangles are a result of a destructive 
neurological process rather than a direct cause (Alzheimer's Breakthrough, 2005). The 
AD mouse model was also used in a vaccine trial to clear the plaques once they had 
formed (Schenk et al, 1999).  The vaccine restored neurological performance in the mice, 
and is currently in phase II human clinical trials at Elan Pharmaceuticals. 
 
ONCOMOUSE 
 A third mouse that was used as a disease model is the Oncomouse.  This mouse 
was originally created by Harvard and was the first animal to ever be patented (Leder and 
Stewart, 1984).  Oncomouse has been genetically engineered to develop specific forms of 
cancer.  This mouse’s germ cells and somatic cells contain an activated human oncogene 
sequence (discussed below) that has been introduced into the animal at an early 
embryonic stage to ensure that the oncogene is present in all the animals’ cells.  This will 
increase the chances of the mouse developing malignant tumors, so it can be used to test 
various potential anti-cancer treatments. 
 Oncomice have been created that carry either the v-Ha-ras or the c-myc gene 
driven by the mouse mammary tumor virus (MMTV) promoter/enhancer (Sinn, 1987).  
These to genes are important to cellular growth, and ras has been found to cause cancer 
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when mutated.  When these two mouse strains are crossed, the mouse develops 
accelerated tumor formation in its cells.  Using this animal model cancer can be studied, 
and better insight to what causes cancer can be learned.  Potential anti-tumor compounds 
can be tested on the animals to see if the animal has any sign of reduced carcinogenesis.   
 
SMART MOUSE 
 Although not a disease model, this animal was used as a model for what could be 
done to help memory loss in humans.  Joe Z. Tsien, a researcher at Princeton University, 
genetically engineered a smart mouse.  He named the mouse "Doogie" after the boy 
genius in the TV series Doogie Howser, MD (BBC News, 1999).  Doogie was able to 
navigate through mazes better than regular mice, and has shown signs of better 
intelligence and memory through other tests.  This strain of mice also retained into 
adulthood certain brain features of juvenile mice, which, like young humans, are widely 
believed to be better than adults at grasping large amounts of new information. 
 During embryogenesis, a gene in the brain called the NR2B codes for a protein 
that covers the surface of neurons.  It is an efficient receptor for the chemical signal N-
methyl-D-aspartate (NMDA), a neuronal channel protein, which opens when it is bound 
by the amino acid glutamate after its neuron multiply fired. Active NMDA receptors 
allow calcium ions to enter the neuron, making it more sensitive to stimulation. This 
effect is theorized to be responsible for associative memory and thought in the brain. If 
two signals arrive at the same time, maybe one results from seeing a lit match and the 
other results from a sensation of pain, then the receptor is triggered and a memory is 
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formed (Harmon, 1999).  Research has shown that in young animals memory is triggered 
even when the input signals are relatively far apart. 
 
 
Figure-2: Doogie the mouse who exhibited enhanced 
memory and intelligence (BBC News). 
 
 This use of transgenic animals is ethically debatable.  Even if this experiment is 
not performed in humans, it is very useful in the study of memory.  It shows that some 
day we may be able boost human intelligence and it could be used in gene therapy for 
such areas as dementia. 
 
 
Transpharmers 
 Transpharmers are transgenic animals that are genetically altered to produce 
pharmaceutical compounds in either the milk, eggs, or blood. Gene pharming is a 
technology that scientists use to alter an animal's DNA.  These genetically modified 
animals are mostly used to make human proteins that have medicinal value. The protein 
encoded by the transgene is engineered to be secreted in the animal's milk, eggs, or 
blood, and then collected and purified.  However, the mammary gland is the most 
common place they are made to produce the protein.  Livestock such as cattle, sheep, 
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goats, chickens, rabbits, and pigs have already been modified in this way to produce 
several useful proteins and drugs (Gillespie, 2005). 
The most effective approach for creating a transpharmer is to express a protein in 
the mammary gland by using a promoter from a milk protein gene to direct expression.  
An example of this would be Herman the bull, which produced the human protein 
lactoferrin under a beta casein promoter, and his female progeny produced it in their milk 
(Biotech Notes, 1994).  This protein binds to iron, which is an essential part of infant 
growth.  Cow milk does not contain lactoferrin, so infants are given other iron rich 
sources, mother's milk or formula.  Baby Herman's offspring however produced 
lactoferrin at such a low rate that it was not commercialized. The company which created 
baby Herman is Leiden-based Gene Pharming Europe BV who plan on artificial 
inseminating 60 cows with Herman's sperm (Reuters, 1992). 
 The human gene for lactoferrin was inserted into baby Herman's genes at the 
embryonic stage.  Herman was to have children that would produce the pharmaceutical 
compound in their milk.  Even though the children did not produce enough for it to be 
worth commercializing, the scientific benefits from this are numerous. The same 
technology could be used in making other medications produced in milk and then taken 
and purified in large quantities. 
 
 
Xenotransplanters 
 Xenotransplantation describes when an animal organ is transplanted into a human. 
Xenotransplanters are animals genetically altered to better prepare their organs for 
transplantation into human recipients.  This is a very useful technology because there is 
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an enormous backlog of patients needing organ transplants, and the body normally rejects 
the foreign animal organs.  When this occurs, the body could go into hyperacute rejection 
and the immune system will kill the organ by wiping out all cells in it.  The organ will 
turn black and die. 
With past xenotransplants, surgeons could avoid hyperacute rejection by using 
organs from other primates with similar genomes as humans.  But for numerous reasons 
like size of organs and availability due to extinction, biotechnologists have turned to pigs.  
A pig's physiology is similar to that of humans (Pearson, 2003).  However, there are 
drawbacks that come with using pig organs because the surfaces of porcine endothelial 
cells, which line the blood vessels of the donor organs, have molecules that humans don't.  
This can lead to hyperacute rejection or delayed xenografted rejection, which causes 
antibodies and other killer cells to attack the organ. 
 A major cause for these rejections of pig organs is due to a gene in the pigs that 
codes for the enzyme alpha-1,3-galactosyltransferase (GGTA1).  This enzyme codes for 
the sugar alpha-1,3-galactose that is on the surface of the cells in pigs.  This sugar is 
recognized as foreign in humans and causes hyperacute rejection of the organs.  David 
Ayares of Revivicor in Blacksburg, Virginia has found preliminary evidence that pig 
organs engineered to lack GGTA1 can bypass rejection (Pearson, 2003).  
Xenotransplantation has many risks involved, deadly rejection or viruses, but if this 
technology were to be successful the benefits are great. 
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Transgenic Food Sources 
 This classification of transgenic animals involves genetically modifying animals 
to better accommodate the needs of human consumption.  An example of this is when 
growth hormone is incorporated into an animal's genome.  Gene constructs encoding 
growth hormone have been incorporated into the genome of several species of salmon to 
create “superfish”.  These animals show increased growth rates, improved flesh color and 
increased disease resistance (Devlin et al, 1997). 
 One way of getting salmon to grow is to add an antifreeze protein promoter, 
which produces a growth-stimulating hormone in the fish.  This was discovered when 
Choy Hew, Ph.D. accidentally froze a tank of flounder.  When the fish tank was thawed, 
the fish were still alive.  This particular species of fish had a gene that produced an 
antifreeze protein that prevented its tissues from dieing under freezing conditions.  The 
gene that activated this protein, which is normally turned off, was then isolated.  This 
gene was used like a switch to activate the growth-stimulating hormone in the salmon.  In 
the resulting salmon the switch remained on.  These fish grow much faster than 
conventional salmon, but they do not reach the same physical maturity (Lewis, 2001). 
 
 
Figure-3: A transgenic Atlantic salmon, containing an antifreeze 
protein promoter, measured against control siblings (Rome, 2001). 
 27 
CHAPTER 3:  TRANSGENIC ETHICS 
 
 It is true that transgenic animals hold the potential for enormous contributions to 
science and medicine.  What remains uncertain is whether engineering new life and 
modifying existing forms is ethical in modern society.  Technicalities in genetic 
engineering no longer limit the ability of scientists to manipulate life forms.  So now that 
we know how to make such animals, we now use ethics to determine what bounds we 
should use with this new technology.  This chapter will first explore the advantages and 
benefits of creating transgenic animals, along with some concerns from the public and 
other sources. It will also be helpful to observe how people from different religions, 
cultures, and backgrounds perceive this issue because basic principles may be derived 
from past values (Curran and Koszarycz, 2004).  To effectively reason which new 
animals are ethically acceptable and which should be avoided is a balance of their 
medical benefits versus any detriments such as animal suffering.  This chapter will list 
specific transgenic examples and individual applications which cover the varying levels 
of animal suffering ranging from none at all to life threatening.  The final segment of the 
chapter will consist of an evaluation of current practices along with suggested plans of 
action regarding how to proceed with animal transgenesis. 
 
Transgenic Positives 
 The advantages of using transgenic animals can be divided into three broad 
categories:  medical, scientific, and food benefits.  As discussed in Chapter-2, medical 
advantages are seen with disease models like Alzheimer’s mouse and Oncomouse that 
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teach us how diseases initiate and progress (Lemonick et al, 2001).  Such models are 
required for performing experiments not ethical in human beings.  Medical advantages 
are also seen in transpharming models that produce life-saving pharmaceuticals in their 
milk (D’Silva, 1998), and Xenotransplanters that grow organs for human transplants 
(Butler, 2002).  Scientific benefits are seen in some animals engineered to over-express a 
specific protein (or knockouts engineered not to produce a specific protein) to help ellicit 
a newly discovered protein’s function.  Food benefits are seen in superfish that grow 
faster and larger than regular fish.  Basic science and medical research would benefit 
from fewer required lab animals and generation of more accurate data because of a 
greater genetic similarity in the test subjects, for example mice or monkeys 
(Taconic.com).  Agriculturally, farm animals that can produce better products, more 
efficiently while consuming less food themselves would be a valuable commodity.  
Additionally, disease resistance and faster production times offer even more incentive to 
progress (Mepham, 1994).  The potential to successfully utilize transgenic animals is 
huge, as is the possibility of exploiting them. 
 
Transgenic Negatives 
 There are many concerns involved with making transgenic animals, some real 
some products of fear.  Commonly applied to the practice of genetic modification is the 
phrase “playing God,” which can mean that man has become arrogant and disregarded his 
respect for nature, or has otherwise violated nature in some way (Macer, 1990).  
Destroying the “integrity” of the animal genome, in this case applied to the intactness of a 
genome, is a worry of environmentalists (Vorstenbosch, 1993).  The question of interest 
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arises, who is really benefiting: the human species or biotech investors?  The worry that 
animals may be reduced to instruments or tools is important to consider.  Then there is 
the slippery slope argument which says that what can be done with animals may someday 
be done with humans (Schroten, 1997).  The most widely accepted arguments against the 
technology object to animal suffering, and point to preservation of the welfare of 
transgenic animals which is rooted in modern environmental philosophy (Rollin, 1996).  
Also loss of genetic diversity, environmental hazards, and human health risks pose 
questions that must be addressed (Mepham, 1994).  In any case, the primary worry 
remains; will a given experiment result in mutant animals with increased mortality or 
other negative effects on the health and well-being of that animal?  Unfortunately, we 
can’t know until we try. 
 Another fact to keep in mind when discussing the tampering with genes and 
genomes is that we have been doing it for centuries via selective breeding.  Selective 
breeding has given us the broiler chicken which grows to approximately 2 kg in about 40 
days, half the time it took 30 years ago.  The chickens grow muscle faster than the 
skeletal and cardiovascular systems which support it and end up with leg problems and 
heart failure (Christiansen and Sadoe, 2000).  With effects like these on the welfare of 
non-genetically altered animals, few would permit the use of a controversial new method 
to again push the animals to their production limits.   
 
The Beltsville Pigs Ethics  
The dramatic case of the Beltsville pigs is an example of how a promising 
experiment can result in a reduction of animal welfare.  Engineered to produce human 
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Figure 1.  Leaner pork chops from a transgenic pig. 
USDA Agricultural Research Service, 1980. 
Figure 2.  A laser scanning confocal image of an 
Alzheimer’s mouse brain showing normal mouse 
neurons (green), human amyloid beta protein (red), 
and distorted neurites (yellow) telltale features of 
Alzheimer’s disease (Games, Adams, et al, 1995). 
growth hormone, they were expected to grow faster and produce leaner meat (Figure 1).  
Although these goals were accomplished, the pigs suffered from arthritis, stomach lesions 
and gastric ulcers, lack of coordination and muscle weakness (D’Silva, 1998).  It is 
generally agreed that the costs in the suffering of the animals outweighed any benefits 
offered by the transgene recipients, and scientists thus imposed a voluntary moratorium 
on growth hormone experiments.  
Rollin (1996) notes that it is the 
effects of the transgene transfer and 
not the transfer itself that is 
objectionable in this case.  A 
counterargument is that manipulation 
of embryos in vitro results in stress to 
the birth mother and presumably also 
to the unborn animal.  
Alzheimer’s Mouse Ethics 
Not all animals are required to suffer 
to serve the greater good.  In the author’s 
view, an example of an acceptable 
transgenic animal model for human disease 
is Alzheimer’s mouse.  Created by a team of 
experts from across the country, including 
Prof. Adams of WPI, the mouse models 
“express high levels of human mutant β-
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amyloid precursor protein, and the animals progressively develop many of the 
pathological hallmarks of Alzheimer’s disease” (Figure 2) (Games, Adams, et al, 1995).  
What makes this model an ideal candidate for ethical acceptance is that the mice do not 
suffer to any measurable degree, yet this model is essential for continuing research into 
Alzheimer’s therapeutic compounds.  For example, using this mouse model, Elan 
Pharmaceuticals has already developed a vaccine that “can markedly reduce pathology in 
an animal model of the disease” and “may prove beneficial for both the treatment and 
prevention of Alzheimer’s disease” (Schenk et al, 1999).  Elan is currently in phase II 
human clinical trials with their second version of this vaccine.  Figure 3 clearly shows 
that the vaccine works to reduce, even eliminate Aβ plaque formation (panel B, loss of 
brown color) when performed early enough.  
Figure 3.  Panel A 
shows the 
hippocampal region 
of an untreated 
Alzheimer's mouse 
brain with many 
plaques (dark 
brown), while panel 
B shows the same 
area of an 
Alzheimer's mouse 
brain that has been vaccinated (Schenk et al, 1999). 
 
 
Since this model provides a very strong medical benefit, with no observable animal 
suffering, the authors of this report support the continuance of these Alzheimer’s 
experiments. 
 
Transpharming Ethics 
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 Transgenic cows also offer hope to applied transgenesis as they do not suffer in 
producing valuable exogenous proteins in their milk.  These examples make clear that it 
is not unacceptable to create animals with new traits; it becomes objectionable when the 
animals are put in circumstances that are detrimental to their health or cause suffering.   
 The art of making transgenic animals 
has by no means reached perfection.  
Herman, a bull given the human gene for 
lactoferrin with hopes of producing milk 
more similar to the human variety, was the 
only one out of 46 calves to receive the 
gene.  That’s about a 2% success rate, not 
very reliable.  Herman’s semen was used to artificially inseminate other cows to produce 
more altered cattle so the females could transpharm lactoferrin in their milk.  A study on 
the welfare of the transgenic cows was conducted and found a higher frequency of 
anomalies, greater mortality rate in comparison with controls, and higher birth weights 
which often necessitated caesarean section, and increased stress to the mother cow (van 
Reenan and Blokhuis, 1997).  The authors offer three suggestions to prevent harmful 
consequences of transgenesis.  First, improve techniques for handling and manipulating 
embryos to minimize embryo loss; second, systematically evaluate animal health and 
welfare to minimize potential animal suffering; and lastly, use the results of health and 
welfare screenings to positively improve conditions and promote transgenic animal 
welfare.  The authors of this report support the construction of transpharmers, so long as 
Figure 4.  Herman the transgenic bull with five 
daughters.  Natuurinformatie, 2004. 
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Figure 5. A mouse with advanced tumor 
formation. PETA photo gallery, 2002. 
there is no evidence of suffering, and the transpharmed product is used for the common 
good. 
 
Oncomouse Ethics 
 
 The oncomouse is one of the most controversial transgenic animal models in use 
today.  By incorporating an activated oncogene sequence into the germ cells of a mouse, 
researchers hope to ascertain more about carcinogenesis and cancer formation (Leder and 
Stewart, 1984).  Obtaining a more complete 
understanding of what causes cancer, and 
being able to test anti-cancer drugs in mice 
represent strong medical benefits.  But the 
ethical concern with the oncomouse is that it 
usually suffers in order to collect relevant 
information, which is in opposition to the 
principles of animal rights (Figure 5).    It 
becomes necessary to consider the moral implications of producing such a species as well 
as measures of reducing animal suffering (Salvi, 2001).  
 By strongly regulating the use of transgenic mice like the oncomouse, it is 
possible to find a middle-ground where creating and employing the mice is acceptable.  
An approach offered by David Porter (1992) is assigning ethical scores to animal 
experiments.  Several categories are scored from 1 to 5 with 1 being most tolerable and 5 
being the least animal-friendly.  For example, pain likely to be involved may be rated 
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from none at all (1), to severe (5).  Other categories are duration of distress, duration of 
the experiment, and number of animals per experiment.  The idea is to deliberately create 
tension between the two opposing positions (Porter, 1992).  Once a system has been set 
up to regulate experimentation, methods can be sought that minimize animal suffering.  
These may include painkillers and sacrificing the animal before severe damage can be 
done.  Human and animal ethics require that the oncomouse be used cautiously and 
sensibly in research. 
 
Religion and Transgenic Ethics 
Religions may form a base upon which morals and ethics can be founded, 
therefore in a discussion of transgenic animal ethics it is important to take a look at how 
some of the major religions of the world have regarded animals in the past, in addition to 
their current views on transgenesis.  
 Jews and Christians have traditionally opposed animal cruelty and taken the 
stance that animals are not considered sacred as the human soul is.  Also, because they 
lack reason, animals may be reasonably used for human benefit.  The role of the 
domesticated animal has special significance for Christians, for example as the shepherd 
tends to his flock (Curran and Koszarycz, 2004).  This image aims toward love and care 
for all creatures.  Stewardship of the animals of the earth requires responsibility in our 
actions towards them, but helpful interventions are welcomed as God’s will to alleviate 
the pain and suffering caused by sin (Loma Linda University, 1997).  Support for 
transgenic animals relies on their value for the common good. 
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Figure 6.  A Hindu child embraces 
a cow (Sacred Cow, 2004). 
Muslim ethics are guided by the Qur’an and hadith.  The controlling concept is 
that of tawhid or the absolute unity of God.  This principle states that whatever has not 
been forbidden by God is allowed within the boundaries of the Qur’an, meaning that 
animals may be used for the benefit of mankind (Curran and Koszarycz, 2004).  Islam 
welcomes genetic engineering as it does all new discoveries that help ease the suffering 
of humanity.  This justification comes from the hadith, “There should be neither harm nor 
reciprocating injury;” taken to mean “prevention is better than cure” (Islam Online, 
2004). 
Hinduism and Buddhism are two great religions of 
India.  Both believe animals to be vital energetic beings and 
treat them as such.  Reincarnation aids in this concern for 
creatures.  In the Hindu faith, Kaamdhenu is the sacred cow of 
Gods which can fulfill all wishes and desires and is considered 
the mother of all cows (Curran and Koszarycz, 2004).  Village 
life upholds the tradition of cow protection (Figure 6), not 
slaughtering the animal but instead taking dairy products as 
protein sources (Sager, 2003).  This simpler way of life 
would reject the idea of bovine transpharmers in favor of naturally raising cattle. 
 
Xenotransplantation Ethics 
13 people in the United States die everyday 
while waiting for a vital organ transplant (Carnell, 
2000).  With this in mind, researchers have begun 
Figure 7.  One of the five cloned 
single knock-out piglets produced 
by PPL Therapeutics.  AAAS, 2005. 
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work on overcoming the vast rejection mechanisms inherent in xenografts (animal organs 
used in humans).  On January 2, 2002 PPL Therapeutics announced the births of 5 cloned 
transgenic piglets.  Each had one inactive copy of the gene α 1-3 galactosyl transferase 
which adds the sugar alpha-gal to the surface of pig cells (Butler, 2002).   Later in July of 
2002 PPL announced that four more piglets had been born, this time with both copies of 
the alpha-gal enzyme gene knocked-out, another critical step towards harvesting animal 
parts since this enzyme normally adds a type of sugar to the surface of pig cells viewed as 
foreign in humans (Pig donor ‘breakthrough’ claimed, 2002).  Although there is promise, 
the success of xenotransplantation is a long way off.  The main difficulty of hyper-acute 
rejection remains the immune system’s T-cells which can affect the organ months or 
years after the transplant.   
 As xenotransplantation matures and it becomes practicable, the principal worry is 
that diseases present in animal organs could cross over into humans.  It is already known 
that the influenza virus thrives in several species such as humans, pigs and birds.  It has 
also been shown that pig retroviruses can infect human cell lines in vitro.  Instead of 
rejecting the idea because of the possible risks, perhaps we should try to minimize the 
risks with respect to the benefits.  One simple answer would be to use disease free-
animals and keep them in sterile conditions although this would arguably violate the 
welfare of the animal.  A compromise would be to raise the pigs normally, but screen for 
known viruses.  After the Public Health Service issued guidelines for xenotransplantation 
in 2000, activists were quick to opt for the “precautionary principle” meaning to always 
minimize the risk regardless of the possible benefit.  This is not very widely accepted as 
if you normally drive a car you are implicitly rejecting the principle (Carnell, 2000).  In 
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light of the dangers of pathogens potentially crossing the species barrier, other options 
could be morally more acceptable than xenografts, such as using artificial organs to help 
reduce the strain on the organ donation market (Society, Religion and Technology 
Project, 2001).    The welfare of the animal donors themselves cannot be forgotten in the 
midst of these potential medical benefits to humans either.   
 As discussed in Chapter-4, the Animal Welfare Act of 1966 is the main piece of 
legislation that defines how research animals are to be treated.  The act protects “all 
warm-blooded species” but leaves out rats, mice, and birds, all of which are warm-
blooded.  This controversial omission is seen by PETA as a loophole for researchers to 
subject certain species to procedures and conditions that would be illegal for all other 
animals protected by the act.  Organizations like the National Association of Biomedical 
Research oppose changes in legislation arguing that guidelines for use of rats, mice, and 
birds already exist in the National Institutes of Health plan.  The ‘arbitrary’ exclusion of 
these species from the AWA is actually not favored by most researchers.  The majority 
want equal protection for all lab animals including rats, mice, and birds which together 
account for approximately 95 percent of all laboratory animals (“Why Include Rats…”, 
2002).  It is a fair question to ask then why all but 5 percent of research animals are 
excluded from research protection?  
 Overall, the public perception of transgenic animals has not been very favorable, 
and with associations like ‘frankenfoods’ to describe edible transgenic plants, more fears 
over the legitimacy of modifying animal genomes are likely.  Granted, animal rights and 
welfare activists have got a point that animals deserve respect and good treatment, but 
these issues can often be controlled using sensible policies.  Given the strong medical 
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potentials of the various kinds of transgenic animals, and the fact that many do not suffer 
at all, and that the suffering when it does occur can be controlled, an outright ban on 
transgenesis is not a good idea in this author’s opinion.  The potential for transgenics is 
enormous and should not be squelched by fears and lack of information.  Scientists and 
the public can resolve their differences with discussion, and implement rational 
guidelines and regulations for ensuring the safe, effective and ethically acceptable use of 
genetically modified organisms. 
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CHAPTER 4:  TRANSGENIC LEGALITIES 
 
 As Chapter 3 has shown, the ethics of producing transgenic animals is a very 
controversial topic which requires the implementation of legal policies to enforce 
oversight of transgenic experiments to minimize animal suffering while maximizing 
medical benefit.  This chapter will take a closer look at the legislation behind transgenic 
animals.  One prominent concern resides in the intellectual property rights of genetically 
modified animals.  On the positive side, patenting transgenics offers various incentives, 
including stimulating additional biomedical research.  On the other hand, some activists 
have protested the authority of the Patent and Trademark Office to grant any patents on 
animal life.  Both sides of the issue will be presented along with several landmark court 
cases.  The United States, Europe and Canada have reached different conclusions with 
regard to issuing exclusive rights for newly created life forms.  Each decision reflects 
upon differing interpretations of local laws and past rulings on similar cases. 
 
General Patentability Issues 
 In granting patents to inventors, the U.S. Patent and Trademark Office requires 
that a submission satisfy the three requirements of novelty, utility and non-obviousness 
(35 U.S.C. § 101, § 102, § 103).  None of the requirements demands that the invention be 
inanimate or non-living.  Title 35 United States Code § 101 states that “Whoever invents 
or discovers any new and useful process, machine, manufacture, or composition of 
matter, or any new and useful improvement thereof, may obtain a patent therefor, subject 
to the conditions and requirements of this title”  (Bitlaw, 2000). 
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Diamond vs. Chakrabarty 
Biotechnology patent issues did not begin with animals.  In 1972, microbiologist 
Ananda M. Chakrabarty applied for a patent application for his invention of a genetically 
engineered bacteria created by adding two different plasmids to the wild-type organism, 
each of which provided a separate pathway for breaking down components of crude oil .  
The patent usefulness requirement was met by the 
bacteria’s potential to help in the treatment of oil 
spills, novelty was also met as there are no naturally 
occurring bacteria with the same capabilities, and 
finally the non-obvious requirement was clearcut (see 
Figure 1).   
When a patent examiner initially rejected 
Chakrabarty’s claim for the bacteria on the grounds 
that transgenic microorganisms were products of 
nature and not patentable, the scientist appealed and 
took his case to the Supreme Court where Diamond 
vs. Chakrabarty became a landmark case in patent 
law.  The court found that the claim met all three requirements set forth under section 101 
disregarding the examiner’s grounds for refusal, and granted patents for the bacteria 
themselves in addition to exclusive rights for the method of producing it and a carrier 
material floating on water with the bacteria (Diamond v. Chakrabarty, 1980).  The court 
also recognized that potential hazards that could be generated by genetic research should 
Figure 8: An opportunity for 
Chakrabarty's microorganisms to 
fulfill the requirement for utility, 
an oil spill at Mouillie Point, 
South Africa (Richardson, 2000). 
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be met by Congress and the Executive branches and not the Judiciary; thus the only 
obligation of the court was to use current legislation to determine patentability.  The 
judge’s interpretation in this case that the microorganism constituted a “manufacture” or 
“composition of matter” paved the way for subsequent animal patents.   
The Patent and Trademark Office confirmed the decision several years later when 
it issued a statement in the Official Gazette: “The Patent and Trademark Office now 
considers nonnaturally occurring non-human multicellular organisms, including animals, 
to be patentable subject matter within the scope of 35 U.S.C. s. 101.” Also, the animals 
must be “given a new form, quality, properties or combination not present in the original 
article existing in nature in accordance with existing law” (Patent and Trademark Office 
Notice, 1987). With the floodgates opened 
to patenting animal life, the applications 
surged in along with substantial criticism 
directed towards the Patent Office. 
 
Animal Patents 
The first animal patent, on the 
Harvard oncomouse, was awarded in 1988 
just one year after the Patent Office 
affirmed that creatures may be protected 
under patent law.  The oncomouse is a 
mouse given the human ras gene (see Figure 
2) which predisposes it to cancer with much greater frequency than unmodified mice 
Figure 9: Four of the Oncomouse patent 
diagrams showing sequence placement within 
the mouse genome (Leder and Stewart, 1984). 
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(Anderson, 1988).  More details will be discussed on the oncomouse case later.  As of 
September 21, 2003 there have been 454 animal patents issued in the United States, of 
which over half (54%) are designated as disease models (American Anti-Vivisection 
Society, 2003).  In addition to the oncomouse, some other mouse models that have been 
patented include an Alzheimer’s mouse (Stern and Yan, 2000), a model for Kaposi’s 
sarcoma (Lira and Yang, 2000) and an HIV mouse (incapable of viral transmission) 
(Jolicoeur, 1994) just to name a few.  Other animals to receive patent protection now 
include cows, sheep, pigs, birds and fish, as well as macaques and chimpanzees.  In 
addition to patents for animals themselves, new techniques and technologies that enable 
scientists to gain more power over animal genomes are being protected by patents.  For 
example, Avigenics Incorporated has been awarded patents on a “Windowing 
Technology” for creating an aperture through egg shells which enables the creation of 
transgenic chickens, certain to be valuable in both food and drug production markets 
(Avigenics, 2000).  As more and more transgenic applications are discovered, the number 
of biotechnology patents on animals is sure to rise as well. 
 
Harvard and DuPont’s Oncomouse 
The oncomouse was the first patented animal in the world.  The famous “Harvard 
mouse” received patent number 4,736,866 on April 12 of 1988, and continues to be the 
center of the animal patent universe.  This little mouse’s big patent is controversial 
because it gives ownership of a species to a corporation for the first time.  It encompasses 
wide claims which can lead to questions about accessibility, and it is a step forward into 
the uncertain future of biotechnology patent law.  Claim 1 is as follows:  
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1. A transgenic non-human mammal all of whose germ cells and somatic cells 
contain a recombinant activated oncogene sequence introduced into said mammal, 
or an ancestor of said mammal, at an embryonic stage (Leder and Stewart, 1984). 
 
This statement is enormously broad in that it covers any non-human mammal 
which has the sequence of interest and that it lays claim to all the offspring of the animal 
which also contain the activated oncogene.  Given this fact DuPont, which now holds the 
patent, may assert its legal right to challenge anyone who uses the oncomouse without 
permission. 
Control of who receives the mouse is another issue up for discussion. Distribution 
of DuPont’s oncomouse has 
been set up through Taconic, 
an international supplier of 
Murine Pathogen-Free lab 
animals (see Figure 3) (Taconic, 
1998).  Taconic acquired the 
license to distribute the mice with hopes for easier access to researchers.  The company 
also promotes the use of the oncomouse as a promising alternative to exposing lab 
animals to high doses of carcinogenic compounds. 
With such a revolutionary tool on hand, many researchers were concerned that 
DuPont’s licensing of the oncomouse could slow the testing of new therapies.  To 
overcome this problem, DuPont and the US National Institutes of Health negotiated a 
deal in 2000 giving non-for-profit researchers free access to the mouse with the 
stipulation that any commercial use must pay for the mice (Smaglik, 2000).  Even so, 
some scientists who use the mice feel that DuPont’s requirements for free licensing, 
Figure 10: Taconic promotes the use of the oncomouse as 
a safer option than current methods of making cancer 
models (Taconic.com, 2005). 
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which force institutions to comply with a 
contract and submit an annual report, are too 
stringent.  They argue that if required to pay 
the commercial licensing fee, it could well 
create an economic burden that will restrict 
research (Marshall, 2002).  Unfortunately for 
these researchers the patent has been issued 
and the policies that DuPont requests must be 
followed.   This does affect the future of 
animal patents though, because broad claims like the oncomouse patent will not be 
granted so casually anymore; being the first allowed for wider terms than would be 
acceptable today.  Warren Woessner cites two more recent cases where the claims are 
limited to mice and to single genes: a mouse that develops an enlarged prostate gland 
(Pat. No. 5,175,383) and a mouse with depleted mature T-cells (Pat. No. 5,175,384) 
(Woessner, 1999).  In another argument against the extensive scope of the patent, Richard 
Stallman calls the coverage of any mammalian species “arbitrary boundaries that extend 
far beyond what was invented by producing this strain” (Stallman, 2002).  In that author’s 
opinion, patents should be issued on more narrow terms than was done in the oncomouse 
case so that patent holders are not given unreasonable power, to promote competition 
between techniques and technologies, and to reward creativity as was intended by the 
Constitution.   
Europe and Canada have had tribulations of their own over patent protection of 
the Harvard oncomouse.  In 1990, European Patent Office (EPO) examiners initially 
Figure 11: Exclusively licensed by 
oncomouse patent holder Harvard 
University to distribute the oncomouse 
to researchers in both not-for-profit 
and commercial ventures, though with 
differing conditions and fees for each. 
 45 
refused Harvard’s application for the oncomouse because: patents on plants and animals 
are forbidden by the European Patent Convention, the discovery had not been shown to 
be reproducible and that ethical questions regarding transgenic animals should not be 
overseen by patent law (Dickman, 1990).  The appeals board later rejected these three 
grounds and suggested that the examiners scrutinize the issues of ethics and morality.  
DuPont argued for the patent because of the benefits that the European biotechnology 
market could reap from the incentives.  Until the passage of the European oncomouse 
patent in 1992, DuPont protected itself with licensing agreements.  A marked difference 
in the policies of US and European patent law is that the EPO has twice restricted the 
oncomouse patent, first in 2001 from covering all mammals to only rodents, and later in 
2004 adding that mice specifically were the rodent being covered (Cyranoski, 2004).  
Both modifications to the patent came after objections against the existing patent were 
filed and examined. 
In contrast to both the US and Europe, Canada completely rejected the patent for 
the oncomouse in 2002.  The Canadian Supreme court said in its ruling that “A higher 
life form is not patentable because it is not a new ‘manufacture’ or ‘composition of 
matter’” (Check, 2002).  Important consequences to consider about this decision are the 
future of Canadian life-sciences research and biotechnology.  One biotechnology 
association, BIOTECanada, says the ruling will discourage researchers from creating 
better research models, especially transgenic animals with their benefits to science.   
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Negatives for Patenting Animals 
 One grievance against the Patent and Trademark Office is for allowing that 
animals are patentable before ever examining whether they should be patentable 
(Edwards, 2001).  In response, many argue that morality is not one of the three conditions 
that warrant patent protection; the issues of ethics and morality are not suited to the 
Patent and Trademark Office and should instead be taken up instead by Congress 
(Walter, 1998).  As this hasn’t yet been debated, animals are freely patentable as long as 
they fulfill the requirements of utility, novelty and non-obviousness.   
 Religions the world over object to the patenting of life, many taking it to be a 
devaluation of the individual by placing a price tag on it.  Although many religious 
leaders see problems in making wealthier the companies who dump millions into research 
with hopes of wonder drugs and cancer cures, they less often perceive the benefits to 
human health.  Then there is the general problem with how well humans have typically 
behaved when a new technology comes along that offers its users the advantage over 
those without it.  
 Another worry is that all transgenic farm animal patents will be held by a small 
number of corporations which will drive the family farm out of business.  This dispute, 
although outwardly agreeable, does not stand up to examination.  In reality, without 
patents, the owners of transgenic animals would only license their animals to those 
capable of paying: large companies (Walter, 1998).  This latter case would result in real 
problems for the family farms as commercialized farmers would be at a significant 
advantage.  It must also be noted here that currently, the main interest in transgenic 
animals is for medical and scientific research, not farming which further strengthens the 
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case for patentability.  For the arguments against patenting animals, less are actually 
opposed to patents than are opposed to the technology itself, something that may not 
change anytime soon. 
 Then there is the slippery-slope argument again.  Could patenting animals lead to 
human patents?  It is already permissible to patent “purified” genes and animals with 
integrated human genes.  The Patent Office considers non-human multicellular living 
organisms to be patentable.  However, the PTO has not issued a statement defining the 
number of human genes required to make up a human-animal chimera (Edwards, 2001).  
Congress has not decided one way or the other that animals are patentable, only courts 
have ruled that existing laws do not forbid it.  
 
Positives for Patenting Animals 
 The process of creating a good disease model in a transgenic animal is no easy 
feat.  It requires years of development in the lab, talented scientists, and money.  The labs 
and scientists often find the funds they need from large corporations with the means to 
supply financial support both upfront and downstream for a project.  Investments are 
inherently risky and the success of an idea is not always a simple path from point A to 
point B.  Recall the complications of xenotransplatation, how only a few of the required 
steps to overcome hyperacute rejection have been achieved, and many challenges still 
stand in the way.  With money flowing into Universities from industrial giants like 
DuPont, which provided $6 million to Harvard University’s Philip Leder and Timothy 
Stewart (Blaug, 2004), the best case scenario would be a new invention with a patent 
capable of generating revenue.  A further stimulus for allowing the patenting of animals 
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is that this return has the potential to be reinvested and thus help biotechnology grow 
even more.  Without patent protection, these economic incentives would be nonexistent 
and biotechnology as a whole would suffer.  With so much potential to help human health 
and treat disease, it is no longer a question of whether to pursue this type of animal 
research but how we will go about it. 
 Another aspect of patents is that of visibility of new technologies.  More attention 
means less secrecy, and with any luck may lead to increased collaboration which would 
stimulate the field to an even greater extent (Walter, 1998).  The public would also 
benefit from this situation as they would be better equipped to enter into the discussion of 
ethics and laws over transgenic animals, instead of being kept in the dark in the ever 
increasing pace of science.  Against the possible pitfalls of patents granted to transgenic 
animals, the benefits are inescapably more promising.  Current law may need a little 
reworking to be more fitting for biological patents, but what it comes down to is allowing 
the sciences to flourish through incentive programs and industry.  Regarding the authors 
of this IQP, similar to our conclusions on transgenic ethics, we find that the benefits of 
patents covering transgenic animals outweigh the possible risks posed. Also, the risks 
should not be dismissed but rather incorporated into patent law just as the European 
Patent Office has taken objections towards the broadness of the oncomouse patent and 
reformed it to be more specific and reasonable. 
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CONCLUSION 
 
 This report has explored the many facets of transgenic animals, from how they are 
made in the lab, and what uses we have found for them, to some of the ethical and legal 
issues surrounding their use.  In Chapter 1, we looked at the different techniques that 
researchers have successfully used to integrate foreign genetic material into a new host.  
These core technologies have formed a base from which advances in the field of 
biotechnology have sprung.  It must also be noted that the trial and error period involved 
in the early technology developmental stages has been the topic of intense debate which 
should lessen as the science becomes more efficient. 
 The various uses of genetically engineered animals were discussed in Chapter 2.  
Disease models such as the AIDs mouse and the Alzheimer’s mouse have been hugely 
influential in the body of support for transgenic animals as they exhibit the most 
important of potential human benefits: aiding our understanding and treating life 
threatening illness.  The use of animals for testing treatments is necessary because of the 
ethical gulf which prevents us from performing initial tests on humans.  Transpharmers 
represent another means of improving the human condition by producing human proteins 
in their milk, blood or eggs.  The resultant protein can then be purified and used to treat 
medical needs.  Then there is the possibility of spawning animals with organs capable of 
transplantation into humans, xenotransplanters.  With the great need for hearts, kidneys, 
livers and pancreases, a market for xenografts is already in place.  All that remains now is 
the daunting task of overcoming the myriad of hyper-acute rejection mechanisms.  The 
final category is that of transgenic food sources.  Animals that can grow faster on the 
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same amount or less feed than wild type animals are a promising way to help feed the 
world’s growing population.   
 Chapter 3 focused on the ethics of making and using transgenic animals, with pros 
and cons for each category.  The most obvious benefit to humans is from continued 
research using disease models, but dilemmas ensue when people claim that animal 
suffering, “playing God,” and destroying the animal’s integrity are unethical in the use of 
transgenics.  Not all disease models suffer, especially those transgenic animals 
engineered to mimic only a small aspect of a human disease.  Alzheimer’s mouse is such 
an example, only displaying plaque formation in the brain, strong medical benefit to 
serve as a model for blocking plaque formation, with little or no animal suffering.  
Animals modified for food sources are less beneficial towards humans and thus animal 
suffering in these cases does not represent an acceptable balance between the cost (in 
terms of animal suffering) and the benefits for humans.  Not all animals suffer as shown 
by the Alzheimer’s mouse case, but for those that do, like the Oncomouse, pain can be 
partially controlled to a certain extent with painkillers and early sacrifice before tumors 
get out of hand.  Worries over transmission of animal viruses during xenografts are 
numerous but again, by testing and obtaining healthy animals and keeping them in clean 
conditions, these risks can be kept to a minimum.  Ethics can become a major hurdle in 
biotechnology but with proper regulation, the worries posed by activists and others can be 
addressed. 
 Finally, in Chapter 4, patents and laws concerning genetically modified animals 
were introduced.  Protection of laboratory animals has been regulated by the Animal 
Welfare Act, but activists have complained that by not covering mice, rats and birds, the 
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Act is basically useless because 95 percent of lab animals consist of these warm-blooded 
species.  Patent law entered the biotech market in 1987 when it issued a statement 
claiming its authority to grant patents on transgenic animals.  The famous oncomouse 
case ensued which was widely debated, and even rejected in Europe and Canada before 
receiving patent protection in the former market.  Arguments that patents for creatures are 
not moral, hurt family farmers and could lead to patenting humans do not stand up to 
reason.  The fact is, patents provide a means of compensation for the companies that 
invest millions of dollars in research which in turn stimulates further research and 
eventually better treatments.  The benefits of patenting transgenic animals thus outweigh 
the risks. 
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